Folate-peg modified liposome using amphiphilic doxorubicin for tumor targeting

Jong Soo Choi; Bieong Kil Kim; Jae Won Park; Da Bin Jeong; Young Bae Seu; Joo Hyeung Nam; Kyung Oh Doh

Folate-peg modified liposome using amphiphilic doxorubicin for tumor targeting

Jong Soo Choi
, Bieong Kil Kim
, Jae Won Park
, Da Bin Jeong
, Young Bae Seu
, Joo Hyeung Nam
, Kyung Oh Doh

School of Life Science and Biotechnology

Yeungnam University
Kyungpook National University
DGMIF

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

Abstract

Statement of Purpose: Doxorubicin (Dox) approved by FDA is anthracycline antitumor agent and treated to various cancers. However, Dox showed a short retention time and excretion caused by hydrophilic nature. In the previous study, the amphiphilic doxorubicin derivatives modified with cholesterol (L-dox A) were newly synthesized. These compounds also showed a longer retention time than Dox in HeLa and MDAMB 231 cells [1]. The liposomes were widely investigated to target over-expressed receptor in cancer cells such as a folate receptor (FR). Also, the Dox encapsulated liposome (Doxil) allows more time to reach the tumor tissue and then Dox is slowly released. Therefore, in this study, the L-dox A was used to increase the retention time in cancer cells, and PEGylated cholesterol and folic acid modified lipid were used to form the liposome and target the cancer.

Original language	English
Title of host publication	Society for Biomaterials Annual Meeting and Exposition 2019
Subtitle of host publication	The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting
Publisher	Society for Biomaterials
Pages	533
Number of pages	1
ISBN (Electronic)	9781510883901
State	Published - 2019
Event	42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Seattle, United States Duration: 3 Apr 2019 → 6 Apr 2019

Publication series

Name	Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium
Volume	40
ISSN (Print)	1526-7547

Conference

Conference	42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence
Country/Territory	United States
City	Seattle
Period	3/04/19 → 6/04/19

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

Choi, J. S., Kim, B. K., Park, J. W., Jeong, D. B., Seu, Y. B., Nam, J. H., & Doh, K. O. (2019). Folate-peg modified liposome using amphiphilic doxorubicin for tumor targeting. In Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting (pp. 533). (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; Vol. 40). Society for Biomaterials.

Choi, Jong Soo ; Kim, Bieong Kil ; Park, Jae Won et al. / Folate-peg modified liposome using amphiphilic doxorubicin for tumor targeting. Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials, 2019. pp. 533 (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium).

@inproceedings{bcdd87ab1293423ca421756429c2b790,

title = "Folate-peg modified liposome using amphiphilic doxorubicin for tumor targeting",

abstract = "Statement of Purpose: Doxorubicin (Dox) approved by FDA is anthracycline antitumor agent and treated to various cancers. However, Dox showed a short retention time and excretion caused by hydrophilic nature. In the previous study, the amphiphilic doxorubicin derivatives modified with cholesterol (L-dox A) were newly synthesized. These compounds also showed a longer retention time than Dox in HeLa and MDAMB 231 cells [1]. The liposomes were widely investigated to target over-expressed receptor in cancer cells such as a folate receptor (FR). Also, the Dox encapsulated liposome (Doxil) allows more time to reach the tumor tissue and then Dox is slowly released. Therefore, in this study, the L-dox A was used to increase the retention time in cancer cells, and PEGylated cholesterol and folic acid modified lipid were used to form the liposome and target the cancer.",

author = "Choi, \{Jong Soo\} and Kim, \{Bieong Kil\} and Park, \{Jae Won\} and Jeong, \{Da Bin\} and Seu, \{Young Bae\} and Nam, \{Joo Hyeung\} and Doh, \{Kyung Oh\}",

note = "Publisher Copyright: {\textcopyright} 2019 Omnipress - All rights reserved.; 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence ; Conference date: 03-04-2019 Through 06-04-2019",

year = "2019",

language = "English",

series = "Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium",

publisher = "Society for Biomaterials",

pages = "533",

booktitle = "Society for Biomaterials Annual Meeting and Exposition 2019",

}

Choi, JS, Kim, BK, Park, JW, Jeong, DB, Seu, YB, Nam, JH & Doh, KO 2019, Folate-peg modified liposome using amphiphilic doxorubicin for tumor targeting. in Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium, vol. 40, Society for Biomaterials, pp. 533, 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence, Seattle, United States, 3/04/19.

Folate-peg modified liposome using amphiphilic doxorubicin for tumor targeting. / Choi, Jong Soo; Kim, Bieong Kil; Park, Jae Won et al.
Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials, 2019. p. 533 (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; Vol. 40).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - Folate-peg modified liposome using amphiphilic doxorubicin for tumor targeting

AU - Choi, Jong Soo

AU - Kim, Bieong Kil

AU - Park, Jae Won

AU - Jeong, Da Bin

AU - Seu, Young Bae

AU - Nam, Joo Hyeung

AU - Doh, Kyung Oh

PY - 2019

Y1 - 2019

N2 - Statement of Purpose: Doxorubicin (Dox) approved by FDA is anthracycline antitumor agent and treated to various cancers. However, Dox showed a short retention time and excretion caused by hydrophilic nature. In the previous study, the amphiphilic doxorubicin derivatives modified with cholesterol (L-dox A) were newly synthesized. These compounds also showed a longer retention time than Dox in HeLa and MDAMB 231 cells [1]. The liposomes were widely investigated to target over-expressed receptor in cancer cells such as a folate receptor (FR). Also, the Dox encapsulated liposome (Doxil) allows more time to reach the tumor tissue and then Dox is slowly released. Therefore, in this study, the L-dox A was used to increase the retention time in cancer cells, and PEGylated cholesterol and folic acid modified lipid were used to form the liposome and target the cancer.

AB - Statement of Purpose: Doxorubicin (Dox) approved by FDA is anthracycline antitumor agent and treated to various cancers. However, Dox showed a short retention time and excretion caused by hydrophilic nature. In the previous study, the amphiphilic doxorubicin derivatives modified with cholesterol (L-dox A) were newly synthesized. These compounds also showed a longer retention time than Dox in HeLa and MDAMB 231 cells [1]. The liposomes were widely investigated to target over-expressed receptor in cancer cells such as a folate receptor (FR). Also, the Dox encapsulated liposome (Doxil) allows more time to reach the tumor tissue and then Dox is slowly released. Therefore, in this study, the L-dox A was used to increase the retention time in cancer cells, and PEGylated cholesterol and folic acid modified lipid were used to form the liposome and target the cancer.

UR - https://www.scopus.com/pages/publications/85065451947

M3 - Conference contribution

AN - SCOPUS:85065451947

T3 - Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium

SP - 533

BT - Society for Biomaterials Annual Meeting and Exposition 2019

PB - Society for Biomaterials

T2 - 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence

Y2 - 3 April 2019 through 6 April 2019

ER -

Choi JS, Kim BK, Park JW, Jeong DB, Seu YB, Nam JH et al. Folate-peg modified liposome using amphiphilic doxorubicin for tumor targeting. In Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials. 2019. p. 533. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium).

Folate-peg modified liposome using amphiphilic doxorubicin for tumor targeting

Abstract

Publication series

Conference

UN SDGs

Other files and links

Fingerprint

Cite this